1. Guidelines for the management of haemophilia. World federation of haemophilia, 2005
5. C. Barnes et al. Canadian multi-institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT. Haemophilia 2006, 12, 1-6
6. M. Carcao and all. Rituximab for congenital haemophilia with inhibitors: a Canadian experience. haemophilia, 2006, 12, 7-18
11. E. Berntorp “Hemophilia”, 2004
15. Hoots WK. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14, 466-474
17. L. Valentino “Assesing the benefits of FEIBA prophylaxis in hemophilia patients with inhibitors” Haemophilia 2008, 14, suppl.2, p.54
19. K. Fischer, L. Valentino, R. Ljung, V. Blanchette “Prophylaxis for severe haemophilia: clinical challenges in absence as well as in the presence of inhibitors”, Haemophilia (2008), 14 (Suppl.3), 196-201